ISRCTN93793971 https://doi.org/10.1186/ISRCTN93793971

MRC Adjuvant Gastric Infusional Chemotherapy Trial

Submission date	Recruitment status	[_] Prospectively registered
06/04/2000	No longer recruiting	[_] Protocol
Registration date	**Overall study status**	[_] Statistical analysis plan
06/04/2000	Completed	[X] Results
Last Edited	**Condition category**	[_] Individual participant data
28/10/2021	Cancer	

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Ms Monica Verma

Contact details
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA
-
not@provided.com

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
ST02

Study information

Scientific Title
MRC Adjuvant Gastric Infusional Chemotherapy Trial

Acronym
MAGIC

Study objectives
To investigate whether peri-operative chemotherapy prolongs survival

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Study design
Two armed, randomised controlled trial

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Not specified

Study type(s)
Not Specified

Participant information sheet

Health condition(s) or problem(s) studied
Gastrointestinal cancer

Interventions
Three cycles of pre- and post-operative ECF (Epirubicin, Cisplatin and 5-Fluorouracil) chemotherapy versus surgery alone.
Follow-up: all patients will be followed 6 monthly to 2 years then annually until death.

Intervention Type
Drug

Phase
Phase III

Drug/device/biological/vaccine name(s)
Chemotherapy

Primary outcome measure
1. Survival time
2. Disease-free survival
3. Quality of life
4. Tumour response

Secondary outcome measures
Not provided at time of registration

Overall study start date
20/06/1994

Completion date
31/12/2001

Eligibility

Key inclusion criteria
1. Histologically proven adenocarcinoma (Stage II or greater) of the lower third oesophagus or stomach, that is considered to be non-urgently resectable with no evidence of distant metastasis
2. Suitable and fit for cytotoxic chemotherapy
3. WHO performance status of 0 or 1

Participant type(s)
Patient

Age group
Not Specified

Sex
Not Specified

Target number of participants
500

Key exclusion criteria
1. Other malignant disease other than non-melanomatous skin cancer or in situ carcinoma of the cervix;
2. previous cytotoxic chemotherapy or radiotherapy

Date of first enrolment
20/06/1994

Date of final enrolment
31/12/2001

Locations

Countries of recruitment

England

United Kingdom

Study participating centre
MRC Clinical Trials Unit
London
United Kingdom
NW1 2DA

Sponsor information

Organisation
Medical Research Council (MRC) (UK)

Sponsor details
20 Park Crescent
London
United Kingdom
W1B 1AL
+44 (0)20 7636 5422
clinical.trial@headoffice.mrc.ac.uk

Sponsor type
Research council

Website
http://www.mrc.ac.uk

Funder(s)

Funder type
Research council

Funder Name
Medical Research Council (UK)

Alternative Name(s)
Medical Research Council (United Kingdom), UK Medical Research Council, MRC

Funding Body Type
Government organisation

Funding Body Subtype
National government

Location
United Kingdom

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan
Not provided at time of registration

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	Results	06/07/2006		Yes	No
Plain English results			28/10/2021	No	Yes